Is Johnson & Johnson Stock Outperforming the Dow?

Is Johnson & Johnson Stock Outperforming the Dow? Johnson & Johnson location sign-by JHVEPhoto via iStock Aritra Gangopadhyay Thu, May 28, 2026 at 12:31 PM GMT+2 2 min read New Brunswick, New Jersey-based Johnson & Johnson (JNJ) engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. The company has a market cap of $554.

1 billion and operates in two segments, Innovative Medicine and MedTech. Companies with a market capitalization of $200 billion or more are typically referred to as "mega-cap stocks. " JNJ fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the general drug manufacturers industry.

More News from Barchart Dear Intel Stock Fans, Mark Your Calendars for June 2 Why Micron Stock Might Have a Math Problem Palantir Might Soon Take Over the Intelligence Agencies. Here’s What It Means for PLTR Stock Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know.

Sign up now! However, JNJ stock is down 8. 1% from its 52-week high of $251.

71 touched on Mar. 02. Moreover, JNJ has been on a downward trajectory lately, declining 6.

9% over the past three months and lagging behind the Dow Jones Industrials Average ($DOWI), which rose 3. 4% during the same period. www.

barchart. com Zooming out a little further, the scenario changes. Over the past 52 weeks, JNJ has surged 50.

9%, rallying DOWI’s 19. 6% gain. JNJ has also been trading above its 200-day moving average since last year, showcasing long-term bullish strength.

The stock has, however, traded below its 50-day moving average since this week. www. barchart.

com On Apr. 14, JNJ stock rose marginally following the release of its Q1 2026 earnings. The company’s revenue for the quarter amounted to $24.

06 billion, surpassing Wall Street’s estimates. Moreover, its adjusted EPS came in at $2. 70, also topping the Street’s forecasts.

Johnson & Johnson expects full-year earnings in the range of $11. 45 to $11. 65 per share, with revenue in the range of $100.

3 billion to $101. 3 billion. When stacked against its peer, Eli Lilly and Company (LLY), JNJ has outperformed.

Over the past year, LLY stock has surged 49. 3%. Additionally, sentiment on JNJ remains moderately optimistic.

Among the 25 analysts covering the stock, the consensus rating is a “Moderate Buy. ” Its mean price target of $260. 46 suggests 12.

6% upside potential from current price levels. On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes.

This article was originally published on Barchart.